1 / 17

Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779)/RT followed by CCI-779 versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study. .

trory
Télécharger la présentation

Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779)/RT followed by CCI-779 versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study. Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  2. Disclosures Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  3. Background: preclinical mTOR inhibition Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  4. Background: mTOR inhibition at recurrence Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  5. Main eligibility criteria Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  6. EORTC 26082/22081: Study Design Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  7. EORTC 26082/22081: Endpoints Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  8. Baseline characteristics at randomization Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  9. EORTC 26082/22081: Accrual Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  10. EORTC 26082/22081: Progression-free survival Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  11. EORTC 26082/22081: Overall survival Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  12. EORTC 26082/22081:Primary endpoint: ITT Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  13. EORTC 26082/22081 vs 26981 Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  14. EORTC 26082/22081: Temsirolimus delivery Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  15. EORTC 26082/22081: Safety analysis Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  16. Conclusions Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

  17. Acknowledgments Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

More Related